Medical technology firm Carl Zeiss Meditec has received CE mark approval for its Plex Elite 9000 swept-source OCT platform.
Plex Elite 9000 has been developed to facilitate discovery of new clinical applications for the diagnosis and treatment of eye disease.
By providing OCT and OCT angiography imaging, the system enables researchers to study the critical retinal microstructures and microvasculature of the eye, including vitreous, retina and choroid.
The platform allows researchers to evaluate early mechanisms for micro and neo-vascularization and explore the predictors of progression of retinal and choroidal pathology.
It will also help to understand choroid physiopathology and evaluate mechanisms of retina and choroid response to therapy.
Carl Zeiss Meditec president and CEO Ludwin Monz said: "Collaboration between scientific and medical researchers and industry brought OCT to real-world clinical practice.
"Zeiss introduced the first commercially available ophthalmic OCT in 1996. Now 20 years later, collaboration between clinical researchers and ZEISS is crucial again to bring OCT to the next level, to advance its applications and to make the next generation accessible for daily practice."
The company is showcasing the Plex Elite 9000 at the Association for Research in Vision and Ophthalmology (ARVO) annual meeting in Seattle, which is being held from 1 to 6 May.
Image: Carl Zeiss’ new Plex Elite 9000 system. Photo: courtesy of Carl Zeiss Meditec AG.